1 de 10 sur environ 213 communiqués.
Pacific Biosciences of California, Inc.
KANSAS CITY, Mo. and MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms,...
Ocugen
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Saniona AB
PRESSMEDDELANDE 22 februari 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att bolaget, som ett led i den tidigare...
Saniona AB
PRESS RELEASE February 22, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, as part of its previously announced...
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a...
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...
Inozyme Pharma Inc.
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Saniona AB
PRESS RELEASE January 25, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received approximately USD $2.9 million (SEK 24.2...
Saniona AB
PRESSMEDDELANDE 25 januari 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, tillkännagav idag att Saniona tillförts cirka 2,9...
1 de 10 sur environ 213 communiqués.
